About Us
Leading global manufacturer of active pharmaceutical ingredients with a legacy of innovation and excellence.
Our Capabilities
Industry-leading reach and expertise
250+
250+ APIs
8+
8 Manufacturing sites
2000+
2000+ DMFs (1750+ Active DMFs) across global markets.
329+
329 ANDAs
1100+
1100+ patents globally (125 have been granted).
250+
Experience with complex APIs and formulations supporting early market entries.
250+
Preferred pharma API supplier for pharma companies in more than 80 countries.
Our Journey
We are a company of firsts
1984
Started journey as an API Company
1986
1st API company to export to US at scale for Methyldopa API
1987
1st US FDA approval for Ibuprofen API
1993
1st Indian Pharma Co. to initiate new drug discovery
1997
1st Indian Pharma Co. to license a novel drug to an innovator
2001
1st Asian Pharma Co. (ex-Japan) to list on NYSE
2006
1st Indian Pharma Co. to launch an authorized Gx in US (Finasteride)
2007
Launched World’s 1st monoclonal antibody biosimilar of Rituximab
2010
Launched World’s 1st & India’s only generic of Darbopoetin
2015
Only Indian pharma company included in the Dow Jones Sustainability Index (DJSI) and have been present for 8 years in the Emerging Markets category
2022
WEF recognition in Digital Global Lighthouse Network for use of Industry 4.0
2023
Only Pharma Co. included in Bloomberg GEI and S&P Global Sustainability Yearbook, achieving water positivity in 2023.
2024
100% of strategic suppliers to be compliant with our ESG framework by 2030, alongside recognition through the USP Donor Recognition Program (DRP) award.
2026
First generic company to launch Semaglutide in Canada.
Why We Stand Out
Industry Pioneer
Multiple firsts in pharmaceutical innovation and global expansion
Global Reach
Serving pharmaceutical companies in over 80 countries worldwide
Sustainability
Committed to ESG principles and environmental responsibility